|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001175,
umls-concept:C0011065,
umls-concept:C0029118,
umls-concept:C0035647,
umls-concept:C0087111,
umls-concept:C0205177,
umls-concept:C0205250,
umls-concept:C0243009,
umls-concept:C0392747,
umls-concept:C0443172,
umls-concept:C1032657,
umls-concept:C1050646
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
1999-3-22
|
|
pubmed:abstractText |
To study the relationship between the CD4+ cell response after initiation of protease inhibitors and the occurrence of opportunistic infections and survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2313-20
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9863874-AIDS-Related Opportunistic Infections,
pubmed-meshheading:9863874-Adult,
pubmed-meshheading:9863874-Anti-HIV Agents,
pubmed-meshheading:9863874-CD4 Lymphocyte Count,
pubmed-meshheading:9863874-Cohort Studies,
pubmed-meshheading:9863874-Disease Progression,
pubmed-meshheading:9863874-Female,
pubmed-meshheading:9863874-Follow-Up Studies,
pubmed-meshheading:9863874-HIV Infections,
pubmed-meshheading:9863874-HIV Protease Inhibitors,
pubmed-meshheading:9863874-Humans,
pubmed-meshheading:9863874-Indinavir,
pubmed-meshheading:9863874-Male,
pubmed-meshheading:9863874-Predictive Value of Tests,
pubmed-meshheading:9863874-Prospective Studies,
pubmed-meshheading:9863874-Risk Factors,
pubmed-meshheading:9863874-Ritonavir,
pubmed-meshheading:9863874-Saquinavir
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
|
|
pubmed:affiliation |
Unité INSERM 330, Université Victor Segalen Bordeaux 2, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
